Key Drivers
- Strong Liquidity
- Ongoing Cash Burn
- Share Dilution
AIAI Summary
KYMR is now a high-valuation, event-driven bet on late-2026 KT-621 Phase 2b data: its $1.5B cash runway limits near-term financing risk, but only clearly differentiated efficacy and safety versus established atopic-dermatitis therapies can justify the current ~$9B–$10B valuation, making a cautious, catalyst-focused stance warranted.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •Strong Liquidity
- •Ongoing Cash Burn
- •Share Dilution
KYMR offers strong liquidity and low leverage, but persistent losses, cash burn, dilution, and an elevated valuation warrant caution.
Price Behavior
Key Price Behavior Insights:
- •Support Holding
- •Resistance Test
- •Lower Highs
KYMR is neutral-to-bearish over the last month, with $113–115 support critical and a sustained break above $120 needed to improve momentum.
Sharp rebound from $113.15 on 2026-09-15 to $118.48 on 2026-09-17
Sentiment & News
Key News Insights:
- •KT-621 Enrollment
- •Data Timeline
- •Mixed Ownership
Kymera's completed KT-621 atopic dermatitis enrollment and accelerated data timeline are positive catalysts, though asthma results remain longer-term and institutional flows are mixed.
Near-term investor focus should center on year-end 2026 KT-621 data as a potential valuation catalyst
Similar Companies in Healthcare
Other companies in the same sector with AI ratings